Related Experiment Video
Updated: Aug 21, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Is adjuvant therapy necessary for peritoneal cytology-positive surgical-pathologic Stage I endometrial cancer?
M Dede1, M C Yenen, U Goktolga
1Department of Obstetrics & Gynecology, Gynecologic Oncology Unit, Gülhane Military Medical Academy, Ankara (Turkey).
Objective:
To compare the clinical and laboratory findings between adjuvant therapy performed and not performed on peritoneal cytology-positive patients with cytology-negative cases of surgical-pathologic Stage I endometrial cancer.
Methods:
Twelve peritoneal cytology-positive and 12 negative surgical-pathologic Stage I endometrial cancer cases were used in the study. Adjuvant radiotherapy was performed for six cytology-positive patients (group I); no adjuvant therapy was performed for six cytology-positive (group II) and 12 cytology-negative patients (control group). Pelvic examination, vaginal cytology, serum CA125 levels and routine blood tests were checked at two-month intervals for two years and at six-month intervals for the third year. Abdominopelvic computerized tomography was planned annually.
Results:
There was no statistically significant difference among the three groups and no recurrence in any group.
Conclusion:
We do not recommend adjuvant therapy for cytology-positive patients if the tumor is confined to the uterus.
